tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Khanna A et al. Impact of Flt-3 ligand on donor-derived antigen presenting cells and alloimmune reactivity in heart graft recipients given adjuvant donor bone marrow. 1998 Transpl. Immunol. pmid:10342736
Dresske B et al. WOFIE augments the immunosuppressive potency of FK-506. Window of opportunity for immunological engagement. 1998 Transpl. Immunol. pmid:10342738
Tacrolimus in the prevention of graft rejection: new indication. Helpful alternative to ciclosporin. 1998 Prescrire Int pmid:10342948
Boehringer M et al. Kaposi's sarcoma after renal transplantation: treatment with liposomal doxorubicin. 1999 Nephrol. Dial. Transplant. pmid:10344407
Siemann G et al. Inhibition of cyclic AMP response element-binding protein/cyclic AMP response element-mediated transcription by the immunosuppressive drugs cyclosporin A and FK506 depends on the promoter context. 1999 Mol. Pharmacol. pmid:10347253
Oddis CV et al. Tacrolimus in refractory polymyositis with interstitial lung disease. 1999 Lancet pmid:10347992
Araki T et al. Increases in [3H]FK-506 and [3H]L-N(G)-nitro-arginine binding in the rat brain after nigrostriatal dopaminergic denervation. 1999 Metab Brain Dis pmid:10348311
Möller A et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. 1999 Drug Metab. Dispos. pmid:10348790
Murata M et al. A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation. 1999 Br. J. Haematol. pmid:10354150
Zarifian A et al. Cyclosporine-associated thrombotic microangiopathy in renal allografts. 1999 Kidney Int. pmid:10354295
Yang J et al. Sjögren's syndrome in mice carrying the Ipr(cg) gene and the therapeutic efficacy of an immunosuppressive agent FK506. 1999 Pathol. Int. pmid:10355966
Toung TJ et al. Neuroprotective FK506 does not alter in vivo nitric oxide production during ischemia and early reperfusion in rats. 1999 Stroke pmid:10356112
Muramatsu K et al. Limb allotransplantation in rats: combined immunosuppression by FK-506 and 15-deoxyspergualin. 1999 J Hand Surg Am pmid:10357540
Cheng HH et al. Oligomerization state influences the degradation rate of 3-hydroxy-3-methylglutaryl-CoA reductase. 1999 J. Biol. Chem. pmid:10358074
Cao S et al. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus. 1999 Pediatr Transplant pmid:10359027
Doolabh VB and Mackinnon SE FK506 accelerates functional recovery following nerve grafting in a rat model. 1999 Plast. Reconstr. Surg. pmid:10359255
Johnson KL and Lawen A Rapamycin inhibits didemnin B-induced apoptosis in human HL-60 cells: evidence for the possible involvement of FK506-binding protein 25. 1999 Immunol. Cell Biol. pmid:10361256
Gummert JF et al. Newer immunosuppressive drugs: a review. 1999 J. Am. Soc. Nephrol. pmid:10361877
Kanoh S et al. Effect of FK506 on ATP-induced intracellular calcium oscillations in cow tracheal epithelium. 1999 Am. J. Physiol. pmid:10362712
Jiang H et al. Tacrolimus versus cyclosporin A: a comparative study on rat renal allograft survival. 1999 Transpl. Int. pmid:10363590